The European Commission has approved a new combination use of Johnson & Johnson’s Tecvayli (teclistamab) for multiple myeloma, backed by trial data showing a striking reduction in the risk of the cancer worsening.

The approval covers teclistamab combined with daratumumab for adults with relapsed or refractory multiple myeloma who have had at least one prior treatment.

What multiple myeloma is

Myeloma is a cancer of plasma cells — the antibody-producing cells of the immune system — which accumulate in bone marrow, crowding out normal blood production and producing bone destruction, kidney damage, anemia and susceptibility to infection.

It remains incurable. The treatment pattern is one of successive remissions: patients respond to therapy, relapse, move to the next regimen, respond again, and relapse again — with remissions typically shortening each time and the disease acquiring resistance as it goes.

Extending the duration of any given remission therefore matters more in myeloma than the phrase “progression-free survival” usually conveys. It is time before the next round of treatment begins, in a sequence with a finite number of rounds available.

How teclistamab works

Teclistamab is a bispecific antibody grabbing both BCMA, a protein on myeloma cells, and CD3, on T cells — physically bringing the immune system into direct contact with the cancer.

The mechanism is worth appreciating. A conventional antibody marks a cancer cell and hopes the immune system responds. A T-cell engager forces the interaction: one arm holds the tumour cell, the other grips a T cell and activates it, creating a synapse that would not otherwise form. The T cell does not need to have recognised the cancer independently.

BCMA is a well-chosen target because it is expressed on plasma cells and very little else, which limits collateral damage — and it is the same target as several myeloma CAR-T therapies, with the advantage that a bispecific antibody is off-the-shelf rather than manufactured per patient.

The data

Approval rests on the Phase 3 MajesTEC-3 trial: 291 patients received teclistamab plus daratumumab versus 296 on standard care (daratumumab with dexamethasone plus pomalidomide or bortezomib).

The combination cut the risk of disease progression or death by 83.4% — hazard ratio 0.17 — and over 90% of patients progression-free at six months remained so at three years.

Reading a hazard ratio of 0.17

This is an unusually large effect, and it deserves context rather than acceptance at face value.

Hazard ratios in oncology trials commonly fall between 0.6 and 0.8, representing meaningful but incremental improvement. A ratio of 0.17 means the treated group experienced progression or death at roughly one-sixth the rate of the comparator — a magnitude more often seen when a genuinely new mechanism enters a setting where existing options are weak.

The comparator here was active and reasonable rather than a straw man — daratumumab-based combinations are standard care in this setting. That strengthens the result considerably.

The three-year durability figure is arguably the more meaningful one. In a relapsing disease, the question is not only whether remission is achieved but whether it holds, and over 90% of six-month responders still progression-free at three years describes durability rather than depth.

Why combining with daratumumab makes sense

Daratumumab targets CD38, another protein on myeloma cells, through a different mechanism — and it is already the backbone of standard care in this setting.

Adding a T-cell engager attacks the same cancer through an independent route, and there is a plausible synergy: daratumumab has effects on immune cell populations that may influence how well T-cell-engaging therapy works. Building on an established backbone rather than replacing it is also the more straightforward path to adoption.

The safety consideration

T-cell engagers carry characteristic toxicity. Forcing T cells to activate against a target releases inflammatory signals, producing cytokine release syndrome — fever, low blood pressure and, at severity, organ dysfunction — and neurological effects can occur.

These are typically managed with step-up dosing and monitoring during initiation, which in practice means the first doses are given where patients can be observed. That has real implications for where treatment can be delivered and constrains use in community settings.

What moving earlier means

“This new indication…brings forward a new standard of care for patients in Europe,” said J&J’s EMEA haematology lead, Ester in ’t Groen.

Bringing a potent immunotherapy into an earlier line matters because patients treated earlier are generally healthier — better organ function, better marrow reserve, and immune systems less depleted by prior therapy. For a treatment depending on the patient’s own T cells, that last point is not incidental: T-cell engagers work less well in heavily pretreated patients whose T cells are exhausted.

Using the therapy while the immune system can still respond may be part of why the effect size is so large. Regulatory news, not medical advice.